Am­gen dumps ear­ly-stage CD38xCD3 bis­pe­cif­ic as 3 pro­grams are side­lined by tri­al set­backs

Five years af­ter Am­gen $AMGN agreed to wa­ger up to $1.8 bil­lion on an al­liance with Xen­cor that spot­light­ed their pre­clin­i­cal bis­pe­cif­ic T cell en­gager pro­gram di­rect­ed at CD38 and CD3 for mul­ti­ple myelo­ma, the big biotech is walk­ing away from the pro­gram — one of 3 that were scut­tled on tri­al set­backs.

In a re­view of R&D ac­tiv­i­ties for Q2 Tues­day evening, Am­gen not­ed:

Phase 1 de­vel­op­ment of AMG 424, a CD38-CD3 XmAb an­ti­body has been stopped, with rights re­vert­ing to Xen­cor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER